Skip to main content

Table 1 Antimicrobial activity against respiratory Enterobacterales isolates by region (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Regiona Antimicrobial MIC (mg/L) %S %I %R
MIC90 Range
Africa/Middle East
(n = 833)
Amoxicillin-clavulanate ≥64 0.5–≥64 37.0 N/A 63.0
Piperacillin-tazobactam 128 ≤0.12–≥256 78.3 5.4 16.3
Aztreonam 64 ≤0.015–≥256 65.2 3.8 31.0
Ceftazidime 64 ≤0.015–≥256 65.5 4.8 29.7
Ceftazidime-avibactam 0.5 ≤0.015–≥256 99.0 N/A 1.0
Cefepime 32 ≤0.12–≥64 66.3 4.8 28.9
Imipenem 2 0.06–≥16 89.9 8.0 2.0
Meropenem 0.12 0.015–≥32 96.8 1.0 2.3
Levofloxacin ≥16 0.03–≥16 71.9 8.6 19.4
Colistin (n = 714)a 0.5 ≤0.06–≥16 97.8 N/A 2.2
Amikacin 4 ≤0.25–≥128 95.8 N/A 4.2
Tigecyclineb 1 0.03–8 98.6 0.0 1.4
Asia/South Pacific
(n = 2033)
Amoxicillin-clavulanate ≥64 ≤0.12–≥64 47.2 N/A 52.8
Piperacillin-tazobactam 128 ≤0.12–≥256 76.7 4.7 18.5
Aztreonam 128 ≤0.015–≥256 66.9 2.9 30.2
Ceftazidime 128 ≤0.015–≥256 65.2 3.3 31.5
Ceftazidime-avibactam 1 ≤0.015–≥256 96.9 N/A 3.1
Cefepime 32 ≤0.12–≥64 74.0 3.3 22.7
Imipenem 2 0.06–≥16 89.5 6.4 4.1
Meropenem 0.12 0.015–≥32 95.5 1.0 3.4
Levofloxacin ≥16 0.015–≥16 66.5 6.7 26.8
Colistin (n = 1824)a 1 ≤0.06–≥16 95.2 N/A 4.8
Amikacin 4 ≤0.25–≥128 94.9 N/A 5.1
Tigecyclineb 1 ≤0.015–≥16 97.9 0.0 2.1
Europe
(n = 6006)
Amoxicillin-clavulanate ≥64 0.25–≥64 41.1 N/A 58.9
Piperacillin-tazobactam 128 ≤0.12–≥256 75.5 4.7 19.8
Aztreonam 128 ≤0.015–≥256 71.3 2.6 26.1
Ceftazidime 128 ≤0.015–≥256 70.4 3.9 25.7
Ceftazidime-avibactam 0.5 ≤0.015–≥256 98.5 N/A 1.5
Cefepime 32 ≤0.12–≥64 76.0 3.8 20.1
Imipenem 2 ≤0.03–≥16 86.6 9.0 4.4
Meropenem 0.12 0.008–≥32 95.0 1.3 3.7
Levofloxacin ≥16 0.008–≥16 72.6 4.7 22.7
Colistin (n = 5172)a 0.5 ≤0.06–≥16 96.6 N/A 3.4
Amikacin 8 ≤0.25–≥128 94.4 N/A 5.6
Tigecyclineb 1 ≤0.015–≥16 98.8 0.0 1.2
Latin America
(n = 1256)
Amoxicillin-clavulanate ≥64 0.5–≥64 42.4 N/A 57.6
Piperacillin-tazobactam 128 ≤0.12–≥256 78.5 4.8 16.7
Aztreonam 128 ≤0.015–≥256 67.0 2.1 30.9
Ceftazidime 64 ≤0.015–≥256 66.4 3.7 29.9
Ceftazidime-avibactam 0.5 ≤0.015–≥256 99.6 N/A 0.4
Cefepime 32 ≤0.12–≥64 70.8 4.3 24.9
Imipenem 2 0.06–≥16 88.4 6.8 4.8
Meropenem 0.12 0.015–≥32 95.8 1.1 3.1
Levofloxacin ≥16 0.015–≥16 68.5 5.7 25.8
Colistin (n = 1074)a 0.5 ≤0.06–≥16 96.6 N/A 3.4
Amikacin 4 ≤0.25–≥128 94.6 N/A 5.4
Tigecyclineb 1 0.06–8 100 0.0 0.0
  1. MIC minimum inhibitory concentration; MIC90 MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant; N/A not applicable
  2. aIsolates of Morganella spp., Proteus spp., Providencia spp. or Serratia spp. were excluded due to intrinsic resistance
  3. bTigecycline EUCAST breakpoints only apply to isolates of Citrobacter koseri and Escherichia coli